+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

CAR T-cell Therapy - Global Market Trajectory & Analytics

  • ID: 5139742
  • Report
  • April 2021
  • Region: Global
  • 112 Pages
  • Global Industry Analysts, Inc
Global CAR T-cell Therapy Market to Reach $8.3 Billion by 2027

Amid the COVID-19 crisis, the global market for CAR T-cell Therapy estimated at US$340.7 Million in the year 2020, is projected to reach a revised size of US$8.3 Billion by 2027, growing at a CAGR of 57.7% over the period 2020-2027. CD19, one of the segments analyzed in the report, is projected to record 49.9% CAGR and reach US$4 Billion by the end of the analysis period. After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the CD22 segment is readjusted to a revised 70.1% CAGR for the next 7-year period.



The U.S. Market is Estimated at $103.7 Million, While China is Forecast to Grow at 55.2% CAGR

The CAR T-cell Therapy market in the U.S. is estimated at US$103.7 Million in the year 2020. China, the world's second largest economy, is forecast to reach a projected market size of US$1.3 Billion by the year 2027 trailing a CAGR of 55.2% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 50.7% and 49.5% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 39.1% CAGR.

Select Competitors (Total 46 Featured):
  • bluebird bio, Inc.
  • CARsgen Therapeutics
  • Celgene Corporation
  • Gilead Sciences, Inc.
  • Novartis AG
Frequently Asked Questions about the Global Market for CAR T-cell Therapy

What is the estimated value of the Global Market for CAR T-cell Therapy?

The Global Market for CAR T-cell Therapy was estimated to be valued at $340.7 Million in 2020.

What is the growth rate of the Global Market for CAR T-cell Therapy?

The growth rate of the Global Market for CAR T-cell Therapy is 57.8%, with an estimated value of $8300.0 Million by 2027.

What is the forecasted size of the Global Market for CAR T-cell Therapy?

The Global Market for CAR T-cell Therapy is estimated to be worth $8300.0 Million by 2027.
Note: Product cover images may vary from those shown

I. METHODOLOGY
II. EXECUTIVE SUMMARY
  • Influencer Market Insights
  • World Market Trajectories
  • Impact of Covid-19 and a Looming Global Recession
  • Table 1: World Current & Future Analysis for CAR T-cell Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
  • Table 2: World 7-Year Perspective for CAR T-cell Therapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2020 & 2027
  • Table 3: World Current & Future Analysis for CD19 by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
  • Table 4: World 7-Year Perspective for CD19 by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2020 & 2027
  • Table 5: World Current & Future Analysis for CD22 by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
  • Table 6: World 7-Year Perspective for CD22 by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2020 & 2027

III. MARKET ANALYSIS
  • Table 7: USA Current & Future Analysis for CAR T-cell Therapy by Antigen - CD19 and CD22 - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
  • Table 8: USA 7-Year Perspective for CAR T-cell Therapy by Antigen - Percentage Breakdown of Value Sales for CD19 and CD22 for the Years 2020 & 2027
  • Table 9: Canada Current & Future Analysis for CAR T-cell Therapy by Antigen - CD19 and CD22 - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
  • Table 10: Canada 7-Year Perspective for CAR T-cell Therapy by Antigen - Percentage Breakdown of Value Sales for CD19 and CD22 for the Years 2020 & 2027
  • Table 11: Japan Current & Future Analysis for CAR T-cell Therapy by Antigen - CD19 and CD22 - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
  • Table 12: Japan 7-Year Perspective for CAR T-cell Therapy by Antigen - Percentage Breakdown of Value Sales for CD19 and CD22 for the Years 2020 & 2027
  • Table 13: China Current & Future Analysis for CAR T-cell Therapy by Antigen - CD19 and CD22 - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
  • Table 14: China 7-Year Perspective for CAR T-cell Therapy by Antigen - Percentage Breakdown of Value Sales for CD19 and CD22 for the Years 2020 & 2027
  • Table 15: Europe Current & Future Analysis for CAR T-cell Therapy by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
  • Table 16: Europe 7-Year Perspective for CAR T-cell Therapy by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2020 & 2027
  • Table 17: Europe Current & Future Analysis for CAR T-cell Therapy by Antigen - CD19 and CD22 - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
  • Table 18: Europe 7-Year Perspective for CAR T-cell Therapy by Antigen - Percentage Breakdown of Value Sales for CD19 and CD22 for the Years 2020 & 2027
  • Table 19: France Current & Future Analysis for CAR T-cell Therapy by Antigen - CD19 and CD22 - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
  • Table 20: France 7-Year Perspective for CAR T-cell Therapy by Antigen - Percentage Breakdown of Value Sales for CD19 and CD22 for the Years 2020 & 2027
  • Table 21: Germany Current & Future Analysis for CAR T-cell Therapy by Antigen - CD19 and CD22 - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
  • Table 22: Germany 7-Year Perspective for CAR T-cell Therapy by Antigen - Percentage Breakdown of Value Sales for CD19 and CD22 for the Years 2020 & 2027
  • Table 23: Italy Current & Future Analysis for CAR T-cell Therapy by Antigen - CD19 and CD22 - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
  • Table 24: Italy 7-Year Perspective for CAR T-cell Therapy by Antigen - Percentage Breakdown of Value Sales for CD19 and CD22 for the Years 2020 & 2027
  • Table 25: UK Current & Future Analysis for CAR T-cell Therapy by Antigen - CD19 and CD22 - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
  • Table 26: UK 7-Year Perspective for CAR T-cell Therapy by Antigen - Percentage Breakdown of Value Sales for CD19 and CD22 for the Years 2020 & 2027
  • Table 27: Rest of Europe Current & Future Analysis for CAR T-cell Therapy by Antigen - CD19 and CD22 - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
  • Table 28: Rest of Europe 7-Year Perspective for CAR T-cell Therapy by Antigen - Percentage Breakdown of Value Sales for CD19 and CD22 for the Years 2020 & 2027
  • Table 29: Asia-Pacific Current & Future Analysis for CAR T-cell Therapy by Antigen - CD19 and CD22 - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
  • Table 30: Asia-Pacific 7-Year Perspective for CAR T-cell Therapy by Antigen - Percentage Breakdown of Value Sales for CD19 and CD22 for the Years 2020 & 2027
  • Table 31: Rest of World Current & Future Analysis for CAR T-cell Therapy by Antigen - CD19 and CD22 - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
  • Table 32: Rest of World 7-Year Perspective for CAR T-cell Therapy by Antigen - Percentage Breakdown of Value Sales for CD19 and CD22 for the Years 2020 & 2027

IV. COMPETITION
  • Total Companies Profiled: 46
Note: Product cover images may vary from those shown